Page 55 - Catalysing Chemicals WIP (Version 2.0) FINAL ARTWORK.cdr

The Challenges

• India’s growing • India’s public • Developing • Additionally, • Pharmaceutical
prosperity has spending on new medicines responsible companies
been marked by healthcare is is becoming pharmaceutical produce a
a “dual-disease a little over increasingly companies are higher ratio
burden” - a 1% of the GDP. expensive- under pressure of waste per
continuing rise This is well investments to research kilogram of
in communicable below China’s of almost USD drugs that product, when
diseases and a and America’s 1 billion are produce less compared
spurt in lifestyle healthcare required for harmful side to their
diseases. A spend, to developing an effects. peers, such as
changing address the innovative polymers bulk,
epidemiological needs of a new drug. fine & petro
profile has meant much larger chemical
increased population manufacturers.
cardio-vascular living below
problems, central the poverty
nervous system line.
disorders and
other chronic
diseases.

India facing
"dual disease"
burden

India's
healthcare spend

1%
of GDP

Photo Credit: BASF

Chemistry Everywhere 51
In Pursuit of Sustainable Development